Germany Post Traumatic Stress Disorder Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
USD 210.44 |
 CAGR |
% |
| Major Markets Players |
德国创伤后应激障碍 (PTSD) 市场，按类型（分离性 PTSD、无并发症 PTSD、共病 PTSD、其他）、治疗类型（药物、心理治疗、软件设备）、给药途径（口服、肠胃外、其他）、年龄组（儿童、成人、老年人）、最终用户（医院、门诊诊所、心理健康中心、家庭医疗保健、其他）、分销渠道（医院药房、零售药房、网上药房等）划分 - 行业趋势和预测到 2030 年。
德国创伤后应激障碍 (PTSD) 市场分析与洞察
创伤后应激障碍 (PTSD) 是一种由恐怖事件引发的心理健康状况——无论是亲身经历还是目睹。症状可能包括闪回、噩梦和严重焦虑，以及对事件无法控制的想法。大多数经历过创伤事件的人可能会暂时难以适应和应对，但随着时间的推移和良好的自我护理，他们通常会好转。如果症状恶化并持续数月甚至数年并干扰日常生活，则被称为患有 PTSD。在出现 PTSD 症状后获得有效治疗对于减轻症状和改善功能至关重要。
德国创伤后应激障碍 (PTSD) 市场预计将在 2023 年至 2030 年的预测期内增长。Data Bridge Market Research 分析称，在 2023 年至 2030 年的预测期内，该市场的复合年增长率为 4.4%，预计到 2030 年将达到 2.1044 亿美元。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制至 2020-2015) |
|
定量单位 |
收入（百万美元） |
|
涵盖的领域 |
按类型（分离性 PTSD、单纯性 PTSD、共病性 PTSD、其他）、治疗类型（药物、心理治疗、软件设备）、给药途径（口服、肠胃外、其他）、年龄组（儿童、成人、老年人）、最终用户（医院、门诊、心理健康中心、家庭医疗保健、其他）、分销渠道（医院药房、零售药房、网上药房和其他） |
|
覆盖国家 |
德国 |
|
涵盖的市场参与者 |
AbbVie Inc.、Viatris Inc、辉瑞公司、礼来公司、武田制药有限公司、Aurobindo Pharma.、阿斯利康、Cipla Inc.、Lupin、Accord Healthcare GmbH、Dr. Reddy's Laboratories Ltd.、Zydus Pharmaceuticals, Inc. 和葛兰素史克集团公司。Teva Pharmaceutical Industries Ltd.、Alkermes。以及诺华公司等。 |
德国创伤后应激障碍 (PTSD) 市场的市场定义
创伤后应激障碍 (PTSD) 是一些人在经历过令人震惊、恐惧或危险的事件后出现的疾病。
它是心理创伤对身体、认知、情感和行为产生的复杂影响。其特征是侵入性思维、噩梦和过去创伤事件的闪回、回避创伤提示、过度警觉和睡眠障碍，所有这些都会导致严重的社交、职业和人际功能障碍。
创伤后应激障碍 (PTSD) 治疗有助于提高患者的思维能力、改变身体活动并重新获得对生活的控制感。创伤后应激障碍的治疗方式包括药物治疗、疗法、自我护理和营养。
近年来，创伤后应激障碍（PTSD）的患病率不断上升以及 PTSD 诊断和治疗技术的进步正在推动市场增长，而高昂的治疗成本和与治疗相关的不良反应正在限制德国创伤后应激障碍 (PTSD) 市场的发展。
德国创伤后应激障碍 (PTSD) 市场动态
驱动程序
创伤后应激障碍 (PTSD) 患病率不断上升。
创伤后应激障碍 (PTSD) 是心理创伤造成的一种复杂的身体、认知、情感和行为后果。其特征是侵入性思维、噩梦和对过去创伤事件的闪回、回避创伤提醒、过度警觉和睡眠障碍，所有这些都会导致严重的社交、职业和人际功能障碍。
PTSD 是一种精神疾病，可能发生在经历或目睹自然灾害、严重事故、恐怖主义行为、战争/战斗或强奸等创伤性事件的人身上，或受到死亡、性暴力或严重伤害威胁的人身上。
因此，每年不断增加的 PTSD 病例呼吁改进 PTSD 患者的诊断流程和技术治疗。
因此，由于 PTSD 患病率不断上升，预计它将成为市场增长的一个驱动因素。
PTSD 诊断和治疗的技术进步。
目前，人们正在使用各种技术，包括心率监测器、脑电图(EEG)、录音机和眼动追踪外围设备，来捕获和分析神经和生理数据，以识别 PTSD 状况的标记。
视频会议正在成为一种可行的方法，为服务不足和地理位置偏远的人群提供精神护理以及个人和团体创伤干预。暴露疗法是治疗创伤后应激障碍的有效方法。暴露疗法是另一种通过想象暴露（即生动地想象恐惧的物体、情况或活动）来减轻创伤后应激障碍症状的疗法，旨在帮助个人克服而不是逃避引起恐惧和心理困扰的刺激。
创伤后应激障碍 (PTSD) 发病率不断上升
PTSD 是一种临床诊断疾病，在经历或目睹涉及实际或可能的死亡、暴力或严重伤害威胁的创伤性事件的所有个人中，约有 20% 会出现这种疾病。创伤性事件的例子包括经历或目睹自然灾害、严重事故、恐怖行为、战争/战斗、强奸，或受到死亡、性暴力或严重伤害的威胁。
每年发病数量的增加促使制造商的政府官员引入创新的诊断技术，预计这将在未来几年推动市场增长。
因此，预计每年新发 PTSD 病例数量的增加将成为市场增长的推动力。
提高患者和医生对创伤后应激障碍治疗的认识
提高认识可增加对患者的治疗和诊断。同时，早期发现 PTSD 将有助于专门研究 PTSD 的治疗师确保患者康复良好。许多患有 PTSD 的人经常处理负面想法和感受，这会极大地影响他们的情绪健康和幸福感。许多患有 PTSD 的人可能会对自己的创伤感到内疚或责任感。因此，提高对 PTSD 的认识有助于患者得到正确的治疗。
因此，患者和医生对 PTSD 治疗认识的提高有望成为市场增长的动力。
限制
治疗费用高昂
创伤后应激障碍 (PTSD) 给个人和社会带来沉重负担。尽管患病率相当低，但高并发率和整体损伤会造成有害的痛苦和高昂的治疗费用。治疗 PTSD 的费用可能相差很大。一些患者可以从政府获得非常低廉的护理，但许多人选择接受私人护理并自掏腰包，一年下来费用很容易高达数千美元。
因此，高昂的治疗成本预计将成为市场增长的主要制约因素。
PTSD 治疗相关的副作用
有几种抗抑郁药可用于治疗创伤后应激障碍，抗抑郁药有几种副作用。它们因药物而异，对人的影响也不同。最常见的副作用包括：口干、恶心、便秘、腹泻、头痛、嗜睡、失眠、高血压或低血压、头晕、性困难、食欲变化导致体重增加或减少、过度出汗——文拉法辛、药物奈法唑酮引起的视力模糊以及药物奈法唑酮引起的严重肝损伤
某些患者可能出现严重情绪和行为变化的风险，包括自杀想法（年轻人出现这种副作用的风险更高）。因此，预计与 PTSD 治疗相关的副作用将阻碍市场增长。
机遇/挑战
医疗支出上涨
一个国家在医疗保健方面的支出及其随时间的增长速度受到多种经济和社会因素的影响，包括医疗保健系统的融资安排和组织结构。特别是，一个国家的整体收入水平与该国人口在医疗保健上的支出之间存在很强的相关性。
心理疗法或药物疗法对患有创伤后应激障碍 (PTSD) 的患者有益，早期预防方法可以避免高昂的增量成本。
成本逐年以较小的幅度不断增加，这可以通过德国法定医疗体系内医疗支出的总体增长来解释
医疗支出的增长预计将增加创伤后应激障碍治疗药物的供应，从而更好地治疗患者，减少人为医疗失误。因此，庞大的医疗支出是一个有利因素，预计将为创伤后应激障碍市场的增长创造巨大机会。
药品批准数量不断增加
联邦药品和医疗器械研究所 (BfArM) 批准的治疗创伤后应激障碍的药物数量不断增加，专家们向欧洲药品管理局 (EMA) 等科学委员会贡献了他们的知识。在整个欧盟和国际范围内，BfArM 为安全有效的药物供应做出了重大贡献。
联邦药品和医疗器械研究所增加了治疗创伤后应激障碍的药物的批准。PTSD 药物获得的这些批准将使该药物被宣布为安全使用并准备好上市后批准。这将导致药品供应和分销到德国地区的发展中市场。因此，产品批准的增加预计将推动市场增长。
药品专利到期
创新药企专利到期改变了市场动态，导致竞争对手在产品专利到期后增加仿制药的生产，从而影响竞争市场的价格变化、压力，以及跨国创新药企的销量和利润的变化
市场上仿制药数量的不断增加增加了市场参与者面临的挑战，现有药品价格的降低影响了市场的收入。
专利终止将导致产品获得批准的机会减少和市场上仿制药的增加，这可能会对市场的增长构成挑战。
最新动态
- 2022 年 3 月，AbbVie 和 Gedeon Richter Plc.（Richter）宣布了一项新的联合开发和许可协议，以研究、开发和商业化新型多巴胺受体调节剂，用于治疗神经精神疾病。此次合作基于 Richter 进行的临床前研究结果，包括选定的几种新化学实体进行开发。AbbVie 和 Richter 已在中枢神经系统 (CNS) 项目上合作了 15 年，包括全球推出的卡利拉嗪 (VRAYLAR/REAGILA) 等产品。此次合作有助于公司拓展业务，并在神经系统疾病方面找到新的创新解决方案和发现。
德国创伤后应激障碍 (PTSD) 市场
德国创伤后应激障碍 (PTSD) 市场细分为类型、治疗类型、给药途径、年龄组、最终用户和分销渠道。这些细分市场之间的增长将帮助您分析行业中的主要增长细分市场，并为用户提供有价值的市场概览和市场洞察，以做出战略决策，确定核心市场应用。
类型
- 分离性创伤后应激障碍
- 无并发症的创伤后应激障碍
- 共病 PTSD
- 其他的
根据类型，德国创伤后应激障碍 (PTSD) 市场分为分离性 PTSD、无并发症 PTSD、共病 PTSD 和其他。
治疗类型
- 药物
- 心理治疗
- 软件设备
根据程序类型，德国创伤后应激障碍 (PTSD) 市场分为药物治疗、心理治疗和软件设备。
给药途径
- 口服
- 父母
- 其他的
根据给药途径，德国创伤后应激障碍 (PTSD) 市场分为口服、肠外和其他。
年龄组
- 孩子们
- 成人
- 老年病学
根据年龄组，德国创伤后应激障碍 (PTSD) 市场分为儿童、成人和老年人。
最终用户
- 医院
- 门诊
- 心理健康中心
- 家庭医疗保健
- 其他的
根据最终用户，德国创伤后应激障碍 (PTSD) 市场分为医院、门诊诊所、心理健康中心、家庭医疗保健和其他。
分销渠道
- 医院药房
- 零售药店
- 网上药店
根据分销渠道，德国创伤后应激障碍 (PTSD) 市场分为医院药房、零售药房和在线药房。
竞争格局和德国创伤后应激障碍 (PTSD) 市场份额分析
德国创伤后应激障碍 (PTSD) 市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对迷走神经刺激市场的关注有关。
德国创伤后应激障碍 (PTSD) 市场的一些主要参与者包括 AbbVie Inc.、Viatris Inc、辉瑞公司、礼来公司、武田制药有限公司、Aurobindo Pharma.、阿斯利康、Cipla Inc.、Lupin、Accord Healthcare GmbH、Dr. Reddy's Laboratories Ltd.、Zydus Pharmaceuticals, Inc. 和葛兰素史克集团公司。Teva Pharmaceutical Industries Ltd.、Alkermes 和诺华公司等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 MARKET APPLICATION COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 MERGERS AND ACQUISITION
3.2 PIPELINE ANALYSIS FOR GERMANY POST-TRAUMATIC STRESS DISORDER MARKET
3.2.1 RECENT APPROVALS
3.3 PESTEL ANALYSIS
3.4 PORTER'S FIVE FORCES MODEL
4 REGULATIONS OF GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET
4.1 REGULATORY AND DRUG APPROVAL SCENARIO IN GERMANY
4.2 APPROVAL FRAMEWORK
4.2.1 CLINICAL PRACTICE
4.2.2 MARKETING AUTHORIZATION
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 DRUG TREATMENT RATE BY MATURED MARKETS
5.1.2 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE
5.1.3 KEY PRICING STRATEGIES
5.1.4 KEY PATIENT ENROLLMENT STRATEGIES
6 EPIDEMIOLOGY
6.1 HISTORIC PTSD POOL
6.2 PRESENT PTSD POOL
6.3 FURURE PTSD POOL
6.4 PREVALENCE OF DISSOCIATIVE PTSD BY COUNTRY
6.5 PREVALENCE OF UNCOMPLICATED PTSD BY COUNTRY
6.6 PREVALENCE OF COMORBID PTSD BY COUNTRY
6.7 TREATMENT RATE
7 INTRODUCTION
7.1 OVERVIEW
7.2 IMPACT OF UKRAINE AND RUSSIA WAR ON GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET
7.3 IMPACT ANALYSIS ON DEMAND
7.4 CONCLUSION
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING PREVALENCE OF PTSD.
8.1.2 TECHNOLOGICAL ADVANCEMENTS IN THE DIAGNOSIS AND TREATMENT OF PTSD.
8.1.3 THE INCREASING INCIDENCE OF PTSD
8.1.4 INCREASED AWARENESS AMONG PATIENTS AND DOCTORS REGARDING THERAPIES FOR PTSD
8.2 RESTRAINTS
8.2.1 HIGH COST OF THE TREATMENT
8.2.2 SIDE EFFECTS ASSOCIATED WITH PTSD TREATMENT.
8.3 OPPORTUNITIES
8.3.1 RISING HEALTHCARE EXPENDITURE
8.3.2 RISING APPROVALS OF DRUGS
8.3.3 THE RISING NUMBER OF CLINICAL TRIALS IS EXPECTED TO BOOST THE GROWTH OF THE POST-TRAUMATIC STRESS DISORDER TREATMENT MARKET
8.4 CHALLENGES
8.4.1 PATENT EXPIRY OF DRUGS
8.4.2 RISING ALTERNATIVE THERAPIES
8.5 UNMEET NEEDS
8.5.1 UNMEET REIMBURSEMENT COST
8.5.2 MENTAL HEALTH STATUS AND SOCIAL CONDITIONS OF ASYLUM SEEKERS
9 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TYPE
9.1 OVERVIEW
9.2 UNCOMPLICATED PTSD
9.3 DISSOCIATIVE PTSD
9.4 COMORBID PTSD
9.5 OTHERS
10 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 PSYCHOTHERAPY
10.2.1 COGNITIVE BEHAVIORAL THERAPY
10.2.2 FAMILY THERAPY
10.2.3 STRESS INOCULATION THERAPY
10.2.4 PROLONGED EXPOSURE THERAPY
10.2.5 OTHERS
10.3 MEDICATION
10.3.1 ANTIDEPRESSANTS
10.3.1.1 SELECTIVE SEROTONIN REUPTAKE INHIBITORS
10.3.1.1.1 SERTRALINE
10.3.1.1.2 PAROXETINE
10.3.1.1.3 FLUOXETINE
10.3.1.1.4 CITALOPRAM
10.3.1.1.5 NEFAZODONE
10.3.1.1.6 OTHERS
10.3.1.2 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS
10.3.1.2.1 DULOXETINE
10.3.1.2.2 VENLAFAXINE
10.3.1.2.3 OTHERS
10.3.1.3 TRICYCLIC ANTIDEPRESSANTS
10.3.1.3.1 AMITRIPTYLINE
10.3.1.3.2 IMIPRAMINE
10.3.1.3.3 OTHERS
10.3.2 ANTIPSYCHOTICS
10.3.2.1 QUETIAPINE
10.3.2.2 ARIPIPRAZOLE
10.3.2.3 DIVALPROEX
10.3.2.4 LAMOTRIGINE
10.3.2.5 OTHERS
10.3.3 OTHERS
10.4 SOFTWARE DEVICES
10.4.1 PTSD COACH
10.4.2 PE COACH
10.4.3 CPT COACH
10.4.4 OTHERS
11 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET , BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.3 PARENTERAL
11.4 OTHERS
12 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY AGE GROUP
12.1 OVERVIEW
12.2 ADULTS
12.3 GERIATRICS
12.4 CHILDREN
13 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY END USER
13.1 OVERVIEW
13.2 MENTAL HEALTH CENTERS
13.3 HOSPITALS
13.4 OUTPATIENT CLINICS
13.5 HOME HEALTHCARE
13.6 OTHERS
14 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
14.5 OTHERS
15 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GERMANY
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 ABBVIE (2022)
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENT
17.2 VIATRIS INC. (2022)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 PRODUCT PORTFOLIO
17.3 PFIZER INC
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENTS
17.3.5 RECENT DEVELOPMENT
17.4 ELI LILLY AND COMPANY (2022)
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 PRODUCT PORTFOLIO
17.4.4 RECENT DEVELOPMENT
17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (2022)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.6 ACCORD HEALTHCARE GMBH.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENTS
17.7 ALKERMES.
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENTS
17.8 ASTRAZENECA (2022)
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 AUROBINDO PHARMA.
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
17.1 CIPLA INC. (2022)
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 DR. REDDY'S LABORATORIES LTD
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 GLAXOSMITHKLINE GROUP OF COMPANIES.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 LUPIN (2022)
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 NOVARTIS AG
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENTS
17.15 TEVA PHARMACEUTICAL INDUSTRIES LTD.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.16 ZYDUS PHARMACEUTICALS, INC. (2022)
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 2 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 3 GERMANY PSYCHOTHERAPY IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 4 GERMANY MEDICATION IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 5 GERMANY ANTIDEPRESSANTS IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 6 GERMANY SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 7 GERMANY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 8 GERMANY TRICYCLIC ANTIDEPRESSANTS IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 9 GERMANY ANTIPSYCHOTICS IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 10 GERMANY SOFTWARE DEVICES IN POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 11 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 12 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 13 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 14 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : SEGMENTATION
FIGURE 2 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : DATA TRIANGULATION
FIGURE 3 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : DROC ANALYSIS
FIGURE 4 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : MARKET APPLICATION COVERAGE GRID
FIGURE 8 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : DBMR MARKET POSITION GRID
FIGURE 9 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET : SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF POST-TRAUMATIC STRESS DISORDER IN POPULATION ARE EXPECTED TO DRIVE THE GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET IN THE FORECAST PERIOD
FIGURE 12 UNCOPLICATED PTSD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET
FIGURE 14 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TYPE, 2022
FIGURE 15 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 16 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 17 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TREATMENT, 2022
FIGURE 19 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TREATMENT, 2023-2030 (USD MILLION)
FIGURE 20 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TREATMENT, CAGR (2023-2030)
FIGURE 21 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 22 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 23 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 24 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 25 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 26 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY AGE GROUP, 2022
FIGURE 27 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 28 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 29 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 30 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY END USER, 2022
FIGURE 31 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 32 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 35 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 36 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 37 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 GERMANY POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
